XZB-0004 is under clinical development by SignalChem Lifesciences and currently in Phase I for Non-Small Cell Lung Cancer. According to GlobalData, Phase I drugs for Non-Small Cell Lung Cancer have an 82% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how XZB-0004’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
XZB-0004 overview
SignalChem Lifesciences overview
SignalChem Lifesciences (SLC) is a biotechnology company that discovers and develops novel therapies for oncology. The company is investigating SLC-391, an orally bioavailable small molecule AXL inhibitors to treat acute myelogenous leukemia and non-small cell lung cancer; and SLC-0111, a carbonic anhydrase IX (CAIX) Inhibitor targeting pancreatic cancer. It is also evaluating additional programs targeting cancer and SARS-CoV-2 (corona virus). SLC provides drug discovery, in-vitro diagnostic development, research and development solutions. The company works in collaboration with pharmaceutical and biopharmaceutical companies to develop its products. SLC is headquartered in Richmond, British Columbia, Canada.
For a complete picture of XZB-0004’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.